Are Analysts Bullish about OraSure Technologies, Inc. (NASDAQ:OSUR) after last week?

June 13, 2018 - By Kurt Siggers

Investors sentiment increased to 1.08 in 2018 Q1. Its up 0.25, from 0.83 in 2017Q4. It increased, as 15 investors sold OraSure Technologies, Inc. shares while 57 reduced holdings. 29 funds opened positions while 49 raised stakes. 54.02 million shares or 0.43% more from 53.79 million shares in 2017Q4 were reported.
Raymond James Fin Services Advsr invested 0.01% of its portfolio in OraSure Technologies, Inc. (NASDAQ:OSUR). Northern Tru Corporation stated it has 0% of its portfolio in OraSure Technologies, Inc. (NASDAQ:OSUR). 10,700 are held by Private Advisor Limited Liability Corp. Pinebridge Invests L P reported 12,715 shares stake. Advisory Ltd Liability invested in 0% or 2,595 shares. Chatham Capital Gru reported 60,250 shares. Numerixs Investment Techs holds 900 shares. Fred Alger accumulated 0.13% or 1.66M shares. Geode Cap Ltd Llc has invested 0% in OraSure Technologies, Inc. (NASDAQ:OSUR). Jpmorgan Chase accumulated 341,717 shares. Gilder Gagnon Howe & Ltd Liability Company holds 0.01% or 27,912 shares. Ameritas Prns Incorporated invested in 4,811 shares. Moreover, Sei Invs has 0% invested in OraSure Technologies, Inc. (NASDAQ:OSUR) for 6,783 shares. Prudential Fin holds 0% in OraSure Technologies, Inc. (NASDAQ:OSUR) or 102,147 shares. Quantbot Ltd Partnership accumulated 25,692 shares or 0.04% of the stock.

Since February 15, 2018, it had 0 buys, and 2 selling transactions for $778,707 activity. Shares for $419,247 were sold by TANG STEPHEN S PHD on Thursday, February 15.

OraSure Technologies, Inc. (NASDAQ:OSUR) Ratings Coverage

Among 3 analysts covering Orasure Technologies (NASDAQ:OSUR), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Orasure Technologies had 3 analyst reports since December 15, 2017 according to SRatingsIntel. Canaccord Genuity maintained OraSure Technologies, Inc. (NASDAQ:OSUR) rating on Friday, February 2. Canaccord Genuity has “Buy” rating and $24.0 target. The stock of OraSure Technologies, Inc. (NASDAQ:OSUR) earned “Hold” rating by Jefferies on Tuesday, February 13. Below is a list of OraSure Technologies, Inc. (NASDAQ:OSUR) latest ratings and price target changes.

13/02/2018 Broker: Jefferies Rating: Hold New Target: $17.5 Maintain
02/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $24.0 Maintain
15/12/2017 Broker: Raymond James Rating: Buy

The stock increased 0.92% or $0.16 during the last trading session, reaching $17.5. About 308,590 shares traded. OraSure Technologies, Inc. (NASDAQ:OSUR) has risen 9.53% since June 13, 2017 and is uptrending. It has underperformed by 3.04% the S&P500.

OraSure Technologies, Inc., together with its subsidiaries, develops, makes, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company has market cap of $1.07 billion. It operates in two divisions, OSUR and DNAG. It has a 34.31 P/E ratio. The firm also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

More news for OraSure Technologies, Inc. (NASDAQ:OSUR) were recently published by: Equitiesfocus.com, which released: “Critical Comparison: Novocure (NVCR) vs. OraSure Technologies (OSUR)” on June 13, 2018. Globenewswire.com‘s article titled: “OraSure Technologies to Present at Jefferies Global Healthcare Conference” and published on May 16, 2018 is yet another important article.

OraSure Technologies, Inc. (NASDAQ:OSUR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: